MolPort-001-792-504

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

33 API Suppliers, 19 USDMF, 10 CEP/COS, 6 JDMF, 3 EU WC, 7 NDC API, 7 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

DOSSIERs // Finished Dosage Formulations

79 Dossiers, 52 FDA Orange Book, 12 Europe, 3 Canada, 5 South Africa, 7 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 25MG, TABLET;ORAL - 50MG, TABLET;ORAL - 75MG, CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 25MG
TABLET;ORAL - 50MG
TABLET;ORAL - 75MG
CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 38 Kerry, 31 BASF, 19 Roquette, 16 Ideal Cures Pvt Ltd, 15 Microlex e.U, 15 Corel Pharma Chem, 14 Seppic, 12 Gangwal Chemicals, 11 Sigachi Industries, 8 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 7 Actylis, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 SPI Pharma, 6 Lonza Capsugel, 6 DFE Pharma, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 ACG Worldwide, 4 Kima Chemical, 3 Evonik, 3 Ingredion Pharma Solutions, 3 Vasa Pharmachem, 3 Pharmatrans-Sanaq, 3 The Dow Chemical Company, 3 Prachin Chemical, 3 DKSH, 2 Seqens, 2 Finar, 2 Nomisma Healthcare, 2 Qualicaps, 2 Rochem International Inc, 1 Clariant, 1 Vertellus, 1 Ulanqab Kema New Material, 1 Nanjing Bold Chemical, 1 Jai Radhe Sales, 1 Pfanstiehl, 1 Aeon Procare, 1 Pharm-RX Chemical, 1 Boai NKY Pharmaceuticals Ltd, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Alcedo Pharmachem

EXCIPIENTS BY APPLICATIONS

78 Coating Systems & Additives, 68 Fillers, Diluents & Binders, 49 Controlled & Modified Release, 32 Direct Compression, 29 Solubilizers, 24 Thickeners and Stabilizers, 24 Granulation, 23 Disintegrants & Superdisintegrants, 20 Film Formers & Plasticizers, 19 Topical, 19 Lubricants & Glidants, 16 Parenteral, 15 Taste Masking, 12 Co-Processed Excipients, 9 Empty Capsules, 9 API Stability Enhancers, 8 Emulsifying Agents, 6 Chewable & Orodispersible Aids, 4 Rheology Modifiers, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents, 2 Coloring Agents

GLOBAL SALES INFORMATION

22 US Medicaid Prescriptions, 21 Finished Drug Prices

MARKET PLACE

9 APIs, 4 DOSSIERS // FDF

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 2 EDQM Standards, 7 USP Standards, 7 Other Ref. Standards

DIGITAL CONTENT

2 Data Compilations & Company Tracker #PharmaFlow, 13 News

Full Screen View

Zhongnan Hospital of Wuhan University

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Therapeutic Effects of Dipyridamole on COVID-19 Patients With Coagulation Dysfunction 2 Coagulation Dysfunction

Details:

HCoV-19 59 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, 60 suppressing hypercoagulability and enhancing immune recovery.

Lead Product(s): Dipyridamole

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 29, 2020

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for MolPort-001-792-504

MolPort-001-792-504

MolPort-001-792-504

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

33 API Suppliers

19 USDMF

10 CEP/COS

6 JDMF

3 EU WC

7 NDC API

7 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

DOSSIERs // Finished Dosage Formulations

79 Dossiers

52 FDA Orange Book

12 Europe

3 Canada

5 South Africa

7 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 25MG

TABLET;ORAL - 50MG

TABLET;ORAL - 75MG

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

38 Kerry

31 BASF

19 Roquette

16 Ideal Cures Pvt Ltd

15 Microlex e.U

15 Corel Pharma Chem

14 Seppic

12 Gangwal Chemicals

11 Sigachi Industries

8 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

7 Actylis

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

7 SPI Pharma

6 Lonza Capsugel

6 DFE Pharma

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

4 ACG Worldwide

4 Kima Chemical

3 Evonik

3 Ingredion Pharma Solutions

3 Vasa Pharmachem

3 Pharmatrans-Sanaq

3 The Dow Chemical Company

3 Prachin Chemical

3 DKSH

2 Seqens

2 Finar

2 Nomisma Healthcare

2 Qualicaps

2 Rochem International Inc

1 Clariant

1 Vertellus

1 Ulanqab Kema New Material

1 Nanjing Bold Chemical

1 Jai Radhe Sales

1 Pfanstiehl

1 Aeon Procare

1 Pharm-RX Chemical

1 Boai NKY Pharmaceuticals Ltd

1 Qianhao Chemical (Hebei) Co., Ltd

1 Alcedo Pharmachem

EXCIPIENTS BY APPLICATIONS

78 Coating Systems & Additives

68 Fillers, Diluents & Binders

CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons